Incyte (WBO:INCY) Short Interest


WBO:INCY Incyte Corp WBO:INCY
87 GF Score
Price €70.36
GF Value €61.46
! 4 Warning Signs
View Full Analysis

What is Incyte Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

WBO:INCY vs MRNA, ROIV, INSM: Short Interest Comparison

For the Biotechnology subindustry, Incyte's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incyte Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Short Interest distribution charts can be found below:

* The bar in red indicates where Incyte's Short Interest falls into.


WBO:INCY
87GF Score
Incyte Corp WBO:INCY
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Incyte (WBO:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of €70.36 is trading 14.5% above its estimated GF Value™ of €61.46.

Key valuation signals for WBO:INCY:

  • Short Interest:
  • GF Value™: €61.46 vs. price of €70.36 (14.5% above fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the WBO:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
87GF Score

Get the complete analysis for WBO:INCY

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.36
Price
€61.46
GF Value